European Union
Regulator: Not represented
not_approved
As of: 9/9/2026 · Temporal status not established
Regulatory context incomplete: regulator.
Scientific intelligence record
Experience 2.0
Growth hormone secretagogue peptide
Synthetic hexapeptide growth-hormone secretagogue acting principally through the ghrelin receptor.
Record status
Traceability partial
Last meaningful update: 9/9/2026
Governed reviewed evidence
25
Governed records, not an efficacy score or total literature count.
Evidence boundary
0 / 25
Claim-linked support versus recorded evidence.
Research gaps
1
Unresolved questions remain visible.
Human experience
Below display gate
Observations never become clinical evidence.
Human experience · separate evidence stream
Eligible observations remain below the privacy and reliability threshold. WPF will not convert a handful of reports into a percentage, trend, or clinical claim.
Observation is valuable human context. It is not evidence of causation, efficacy, or safety.
Public display gate
n ≥ 20 eligible observations
Exact progress remains private before the threshold.
Intelligence snapshot
A compact view of what is represented, what remains unresolved, and how completely the record can be traced.
Governed reviewed evidence
25
Reviewed database records promoted through the governed publication workflow.
Contradictions
0
Conflicting evidence relationships that remain visible.
Research gaps
1
Questions the current record identifies as unresolved.
Connected media
0
Media records explicitly linked to this scientific record.
What we know
The project separates represented evidence from qualification, contradiction, uncertainty, and what the evidence does not establish.
This does not mean the scientific literature contains no findings. It means no reviewed institutional claim has been represented here.
Scientific context
Existing reviewed chemistry is preserved as scientific context. Chemistry and mechanism information do not establish clinical efficacy or safety.
Chemical identity describes the recorded molecular information. It does not establish biological activity, clinical efficacy, safety, or therapeutic suitability.
Explore further
Move from this peptide record into the project's broader evidence, research, comparison, and methodology systems.
Research
Chronology, unresolved research questions, opportunities, and researcher activity remain descriptive rather than evaluative.
1996 · study · Temporal status not established
The Journal of clinical endocrinology and metabolism
1998 · study · Temporal status not established
Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
1999 · study · Temporal status not established
Clinical endocrinology
1999 · study · Temporal status not established
International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity
Connections
Connections appear only when they are represented by the project’s underlying records.
institution
institution
institution
Traceability
The experience makes incomplete links visible instead of presenting a false impression of perfect provenance.
Source publication state
A governed source may be verified and approved for publication while its claim-to-evidence link is still incomplete.
Reviewer provenance state
“Human scientist reviewed: no” means that specific source-path attribution is not recorded. It does not silently negate the separate publication-review state.
Claim → Evidence
Incomplete
Evidence → Source
Connected
Source → Original record
Connected
Traceability documents how the project connects statements to records. It does not establish that a source is scientifically valid or that a claim is clinically true.
Incomplete links: claim-to-evidence
Hexarelin-induced growth hormone, cortisol, and prolactin release: a dose-response study.
Observational archive
Observational archive data is intentionally separated from published scientific evidence.
Observational boundary
Insufficient eligible observations are available for display under the current filters.
Insufficient eligible observations are currently represented to display aggregated findings for this peptide.
Regulatory context
Regulatory status is jurisdiction-specific and time-dependent. It is presented as context, not as a recommendation for use or a substitute for scientific evidence evaluation.
European Union
Regulator: Not represented
As of: 9/9/2026 · Temporal status not established
Regulatory context incomplete: regulator.
United States
Regulator: Not represented
As of: 9/9/2026 · Temporal status not established
Regulatory context incomplete: regulator.
Research + media
Only media explicitly linked through the project’s relationship system appears here.
No scientifically connected media is currently represented for this peptide.
Sources + provenance
Hexarelin evidence · ranking key
A tier describes the evidentiary role and design strength of a source. It is not a popularity score, proof that every conclusion is correct, or a substitute for claim-level review.
Large, well-conducted randomized trials; prespecified major outcomes; rigorous systematic reviews or meta-analyses; and major regulatory assessments.
Smaller randomized trials, strong prospective cohorts, prespecified secondary analyses, and high-quality comparative-effectiveness studies.
Retrospective cohorts, claims-database studies, pharmacovigilance analyses, mechanistic human research, and well-documented case series.
Case reports, conference abstracts, preclinical research, hypothesis-generating analyses, and expert commentary.
Tier classifies source design and evidentiary role. Confidence reflects risk of bias, sample size, comparator quality, outcome relevance, follow-up, missing data, directness, replication, reporting quality, and whether conclusions stay within the measured results.
peptide explorer
Evidence-class labeling remains visible even when interactive rendering is unavailable. Representative geometry is not an experimentally determined or predicted biological conformation.
Fully specified molecular identity
Modified stereochemistry is exact in notation; the viewer is residue-order only.
Sources: NIH PubChem — Hexarelin / Examorelin · reviewed 2026-09-17
Governed scientific evidence
Duplicate-safe scientific sources under accountable human review. Identified or pending records do not contribute as approved evidence.
Audit view
Human and preclinical evidence remain separate. Source identity, claim-to-source traceability, review dates, conflicts, limitations, and unknowns stay visible rather than being collapsed into one score.
PubMed-indexed clinical trial; journal article; randomized controlled trial examining hexarelin-induced growth hormone, cortisol, and prolactin release: a dose-response study. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed clinical trial; journal article examining does desensitization to hexarelin occur?. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed clinical trial; journal article examining the effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article; review examining we are ageing. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article; review examining the cardiovascular action of hexarelin. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article; research support, non-u.s. gov't examining hexarelin attenuates abdominal aortic aneurysm formation by inhibiting smc phenotype switch and inflammasome activation. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article; research support, n.i.h., extramural; review examining the safety and efficacy of growth hormone secretagogues. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining hexarelin modulates lung mechanics, inflammation, and fibrosis in acute lung injury. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article; review examining growth hormone in obesity. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining new active series of growth hormone secretagogues. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining sars-cov-2 rna dependent rna polymerase (rdrp) - a drug repurposing study. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article; research support, non-u.s. gov't examining hexarelin as a test of pituitary reserve in patients with pituitary disease. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining hexarelin--evaluation of factors influencing oral bioavailability and ways to improve absorption. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article; review examining the cd36-pparγ pathway in metabolic disorders. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article; research support, non-u.s. gov't examining hexarelin attenuates atherosclerosis via inhibiting lox-1-nf-κb signaling pathway-mediated macrophage ox-ldl uptake in apoe-/- mice. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining kinetics and disposition of hexarelin, a peptidic growth hormone secretagogue, in rats. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining modulation of pten by hexarelin attenuates coronary artery ligation-induced heart failure in rats. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining ghrelin receptor agonist hexarelin attenuates antinociceptive tolerance to morphine in rats. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining the growth hormone secretagogue hexarelin protects rat cardiomyocytes from in vivo ischemia/reperfusion injury through interleukin-1 signaling pathway. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article; research support, non-u.s. gov't examining improvement of cardiomyocyte function by in vivo hexarelin treatment in streptozotocin-induced diabetic rats. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining using synchrotron radiation imaging techniques to elucidate the actions of hexarelin in the heart of small animal models. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed comparative study; journal article; research support, non-u.s. gov't examining natural (ghrelin) and synthetic (hexarelin) gh secretagogues stimulate h9c2 cardiomyocyte cell proliferation. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article; research support, non-u.s. gov't examining hexarelin protects cardiac h9c2 cells from angiotensin ii-induced hypertrophy via the regulation of autophagy. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article; research support, non-u.s. gov't examining hexarelin protects h9c2 cardiomyocytes from doxorubicin-induced cell death. Machine-staged source candidate; findings and limitations require accountable review before publication.
PubMed-indexed journal article examining hexarelin modulation of mapk and pi3k/akt pathways in neuro-2a cells inhibits hydrogen peroxide-induced apoptotic toxicity. Machine-staged source candidate; findings and limitations require accountable review before publication.
1999 · study · Temporal status not established
Clinical endocrinology
2000 · study · Temporal status not established
Drug metabolism and disposition: the biological fate of chemicals
2001 · study · Temporal status not established
The Journal of pharmacy and pharmacology
2001 · study · Temporal status not established
Endocrine
2002 · study · Temporal status not established
The Journal of endocrinology
2003 · study · Temporal status not established
Journal of medicinal chemistry
2014 · study · Temporal status not established
BioMed research international
2014 · study · Temporal status not established
Journal of geriatric cardiology : JGC
2017 · study · Temporal status not established
International heart journal
2018 · study · Temporal status not established
Sexual medicine reviews
2018 · study · Temporal status not established
International journal of molecular sciences
2018 · study · Temporal status not established
Physiological reports
2019 · study · Temporal status not established
Peptides
2019 · study · Temporal status not established
Turkish journal of medical sciences
2019 · study · Temporal status not established
Die Pharmazie
2020 · study · Temporal status not established
Heliyon
2021 · study · Temporal status not established
Drug target insights
2021 · study · Temporal status not established
Canadian journal of physiology and pharmacology
2021 · study · Temporal status not established
Frontiers in physiology
2021 · study · Temporal status not established
Pharmaceuticals (Basel, Switzerland)
2022 · study · Temporal status not established
Microvascular research
2026 · regulatory · Temporal status not established
European Union
2026 · regulatory · Temporal status not established
United States
The represented chronology reflects records currently included in the governed dataset and does not claim to represent the entire scientific literature.
No institutional claim record is currently represented for this peptide.
Evidence is missing or not represented as studied; this is not a conclusion that the intervention does not work.
These are bibliographic author identities derived from represented records. Name strings are not proof of unique real-world researcher identity, and publishing organizations are not treated as institutional affiliations.
3 represented evidence records
Years represented: 2000, 2001, 2002
Publishing organizations appearing in records: Drug metabolism and disposition: the biological fate of chemicals, Endocrine, The Journal of endocrinology
2 represented evidence records
Years represented: 1998, 1999
Publishing organizations appearing in records: Clinical endocrinology, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
2 represented evidence records
Years represented: 2003, 2021
Publishing organizations appearing in records: Journal of medicinal chemistry, Pharmaceuticals (Basel, Switzerland)
2 represented evidence records
Years represented: 2001, 2002
Publishing organizations appearing in records: Endocrine, The Journal of endocrinology
2 represented evidence records
Years represented: 2001, 2002
Publishing organizations appearing in records: Endocrine, The Journal of endocrinology
2 represented evidence records
Years represented: 1998, 1999
Publishing organizations appearing in records: Clinical endocrinology, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
3 represented evidence records
Years represented: 2003, 2021
Publishing organizations appearing in records: Drug target insights, Journal of medicinal chemistry, Pharmaceuticals (Basel, Switzerland)
1 represented evidence record
Years represented: 1999
Publishing organizations appearing in records: Clinical endocrinology
1 represented evidence record
Years represented: 2001
Publishing organizations appearing in records: Endocrine
1 represented evidence record
Years represented: 1996
Publishing organizations appearing in records: The Journal of clinical endocrinology and metabolism
1 represented evidence record
Years represented: 2001
Publishing organizations appearing in records: The Journal of pharmacy and pharmacology
1 represented evidence record
Years represented: 2001
Publishing organizations appearing in records: Endocrine
institution
institution
institution
institution
institution
institution
institution
institution
institution
Claim: Not linked · Evidence: 8055781d-46eb-5e82-97d7-0e8aaa8eb593
PMID: 8954038 · DOI: 10.1210/jcem.81.12.8954038
Extraction: not-recorded · Review: verified · Source state: unknown
Machine extracted: no · Human scientist reviewed: no · Externally validated: no
Incomplete path: claim, extraction-status
Does desensitization to hexarelin occur?
Claim: Not linked · Evidence: a3a6fb85-79b4-52c1-bc21-1bf75b042451
PMID: 10990150 · DOI: 10.1016/s1096-6374(98)80039-7
Extraction: not-recorded · Review: verified · Source state: unknown
Machine extracted: no · Human scientist reviewed: no · Externally validated: no
Incomplete path: claim, extraction-status
The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin.
Claim: Not linked · Evidence: 201c61f9-ac7f-52b2-8d8f-1e704df63b19
PMID: 10341859 · DOI: 10.1046/j.1365-2265.1999.00609.x
Extraction: not-recorded · Review: verified · Source state: unknown
Machine extracted: no · Human scientist reviewed: no · Externally validated: no
Incomplete path: claim, extraction-status
We are ageing.
Claim: Not linked · Evidence: 3f97c8c5-bdcf-50d8-a4fa-c58822169de7
PMID: 25045704 · DOI: 10.1155/2014/808307
Extraction: not-recorded · Review: verified · Source state: unknown
Machine extracted: no · Human scientist reviewed: no · Externally validated: no
Incomplete path: claim, extraction-status
The cardiovascular action of hexarelin.
Claim: Not linked · Evidence: 4892999d-fa00-5b37-a43e-d55bebc17e04
PMID: 25278975 · DOI: 10.11909/j.issn.1671-5411.2014.03.007
Extraction: not-recorded · Review: verified · Source state: unknown
Machine extracted: no · Human scientist reviewed: no · Externally validated: no
Incomplete path: claim, extraction-status
Hexarelin attenuates abdominal aortic aneurysm formation by inhibiting SMC phenotype switch and inflammasome activation.
Claim: Not linked · Evidence: e367ca24-1529-5195-9fe1-060b83c69a80
PMID: 34856183 · DOI: 10.1016/j.mvr.2021.104280
Extraction: not-recorded · Review: verified · Source state: unknown
Machine extracted: no · Human scientist reviewed: no · Externally validated: no
Incomplete path: claim, extraction-status
The Safety and Efficacy of Growth Hormone Secretagogues.
Claim: Not linked · Evidence: 99b063a3-37fc-5f09-b16a-c8b47c53e0c6
PMID: 28400207 · DOI: 10.1016/j.sxmr.2017.02.004
Extraction: not-recorded · Review: verified · Source state: unknown
Machine extracted: no · Human scientist reviewed: no · Externally validated: no
Incomplete path: claim, extraction-status
Hexarelin modulates lung mechanics, inflammation, and fibrosis in acute lung injury.
Claim: Not linked · Evidence: 387529f8-aa7a-5de7-a3a5-3822558ed563
PMID: 34871336 · DOI: 10.1164/rccm.201306-1141WS
Extraction: not-recorded · Review: verified · Source state: unknown
Machine extracted: no · Human scientist reviewed: no · Externally validated: no
Incomplete path: claim, extraction-status
Growth hormone in obesity.
Claim: Not linked · Evidence: 43b7a9e0-0c46-5dcb-9518-9d17158f8675
PMID: 10193871 · DOI: 10.1038/sj.ijo.0800807
Extraction: not-recorded · Review: verified · Source state: unknown
Machine extracted: no · Human scientist reviewed: no · Externally validated: no
Incomplete path: claim, extraction-status
New active series of growth hormone secretagogues.
Claim: Not linked · Evidence: 6fda6457-b4c7-5732-9a0e-4c929e8319c6
PMID: 12646029 · DOI: 10.1021/jm020985q
Extraction: not-recorded · Review: verified · Source state: unknown
Machine extracted: no · Human scientist reviewed: no · Externally validated: no
Incomplete path: claim, extraction-status
SARS-CoV-2 RNA Dependent RNA polymerase (RdRp) - A drug repurposing study.
Claim: Not linked · Evidence: 8ab50b7d-659b-50d4-bd32-c8b2f89b84cc
PMID: 32754651 · DOI: 10.1016/j.heliyon.2020.e04502
Extraction: not-recorded · Review: verified · Source state: unknown
Machine extracted: no · Human scientist reviewed: no · Externally validated: no
Incomplete path: claim, extraction-status
Hexarelin as a test of pituitary reserve in patients with pituitary disease.
Claim: Not linked · Evidence: 602b9109-82e1-5b1a-8ca1-b5edfca4ca94
PMID: 10469018 · DOI: 10.1046/j.1365-2265.1999.00828.x
Extraction: not-recorded · Review: verified · Source state: unknown
Machine extracted: no · Human scientist reviewed: no · Externally validated: no
Incomplete path: claim, extraction-status
Hexarelin--evaluation of factors influencing oral bioavailability and ways to improve absorption.
Claim: Not linked · Evidence: aba03549-402c-5929-ad3c-a764d5d2c0c9
PMID: 11578108 · DOI: 10.1211/0022357011776540
Extraction: not-recorded · Review: verified · Source state: unknown
Machine extracted: no · Human scientist reviewed: no · Externally validated: no
Incomplete path: claim, extraction-status
The CD36-PPARγ Pathway in Metabolic Disorders.
Claim: Not linked · Evidence: dcde849e-3e08-514b-910a-48cba1cf719f
PMID: 29883404 · DOI: 10.1172/JCI27794
Extraction: not-recorded · Review: verified · Source state: unknown
Machine extracted: no · Human scientist reviewed: no · Externally validated: no
Incomplete path: claim, extraction-status
Hexarelin attenuates atherosclerosis via inhibiting LOX-1-NF-κB signaling pathway-mediated macrophage ox-LDL uptake in ApoE-/- mice.
Claim: Not linked · Evidence: 74040b60-4199-5463-b3fb-6110814e0dd1
PMID: 31386895 · DOI: 10.1016/j.peptides.2019.170122
Extraction: not-recorded · Review: verified · Source state: unknown
Machine extracted: no · Human scientist reviewed: no · Externally validated: no
Incomplete path: claim, extraction-status
Kinetics and disposition of hexarelin, a peptidic growth hormone secretagogue, in rats.
Claim: Not linked · Evidence: 54ad3a68-ad3f-58db-b5e0-9273dd8e19dc
PMID: 10611139 · DOI: Unavailable
Extraction: not-recorded · Review: verified · Source state: unknown
Machine extracted: no · Human scientist reviewed: no · Externally validated: no
Incomplete path: claim, extraction-status
Modulation of PTEN by hexarelin attenuates coronary artery ligation-induced heart failure in rats.
Claim: Not linked · Evidence: 69a1acb4-0e27-5c7a-bfd1-6a8766572195
PMID: 31091855 · DOI: 10.3906/sag-1812-49
Extraction: not-recorded · Review: verified · Source state: unknown
Machine extracted: no · Human scientist reviewed: no · Externally validated: no
Incomplete path: claim, extraction-status
Ghrelin receptor agonist hexarelin attenuates antinociceptive tolerance to morphine in rats.
Claim: Not linked · Evidence: a30d7950-7958-5f1c-9573-c2fd5f18cb6f
PMID: 32893668 · DOI: 10.1139/cjpp-2020-0218
Extraction: not-recorded · Review: verified · Source state: unknown
Machine extracted: no · Human scientist reviewed: no · Externally validated: no
Incomplete path: claim, extraction-status
The Growth Hormone Secretagogue Hexarelin Protects Rat Cardiomyocytes From in vivo Ischemia/Reperfusion Injury Through Interleukin-1 Signaling Pathway.
Claim: Not linked · Evidence: 05ad457e-711f-55c4-be7b-07f16c7be291
PMID: 28321024 · DOI: 10.1536/ihj.16-241
Extraction: not-recorded · Review: verified · Source state: unknown
Machine extracted: no · Human scientist reviewed: no · Externally validated: no
Incomplete path: claim, extraction-status
Improvement of cardiomyocyte function by in vivo hexarelin treatment in streptozotocin-induced diabetic rats.
Claim: Not linked · Evidence: d535803a-4c83-56a7-ab8b-d458718cc23b
PMID: 29446246 · DOI: 10.14814/phy2.13612
Extraction: not-recorded · Review: verified · Source state: unknown
Machine extracted: no · Human scientist reviewed: no · Externally validated: no
Incomplete path: claim, extraction-status
Using Synchrotron Radiation Imaging Techniques to Elucidate the Actions of Hexarelin in the Heart of Small Animal Models.
Claim: Not linked · Evidence: 284282e3-eb3e-519d-b979-c7303ef20f1b
PMID: 35126171 · DOI: 10.1007/s00424-004-1243-z
Extraction: not-recorded · Review: verified · Source state: unknown
Machine extracted: no · Human scientist reviewed: no · Externally validated: no
Incomplete path: claim, extraction-status
Natural (ghrelin) and synthetic (hexarelin) GH secretagogues stimulate H9c2 cardiomyocyte cell proliferation.
Claim: Not linked · Evidence: 7e7b22ca-ed8b-5d67-99b4-4ec150f771e4
PMID: 12379504 · DOI: 10.1677/joe.0.1750201
Extraction: not-recorded · Review: verified · Source state: unknown
Machine extracted: no · Human scientist reviewed: no · Externally validated: no
Incomplete path: claim, extraction-status
Hexarelin protects cardiac H9C2 cells from angiotensin II-induced hypertrophy via the regulation of autophagy.
Claim: Not linked · Evidence: 34f9d091-6b74-5554-93d0-b67cbd6ba232
PMID: 31526442 · DOI: 10.1691/ph.2019.9324
Extraction: not-recorded · Review: verified · Source state: unknown
Machine extracted: no · Human scientist reviewed: no · Externally validated: no
Incomplete path: claim, extraction-status
Hexarelin protects H9c2 cardiomyocytes from doxorubicin-induced cell death.
Claim: Not linked · Evidence: 93793051-1cb6-56c4-8abd-6bdfa5f2b3cb
PMID: 11322493 · DOI: 10.1385/ENDO:14:1:113
Extraction: not-recorded · Review: verified · Source state: unknown
Machine extracted: no · Human scientist reviewed: no · Externally validated: no
Incomplete path: claim, extraction-status
Hexarelin Modulation of MAPK and PI3K/Akt Pathways in Neuro-2A Cells Inhibits Hydrogen Peroxide-Induced Apoptotic Toxicity.
Claim: Not linked · Evidence: c180a1cc-fbde-586a-875f-205aa2c4175c
PMID: 34066741 · DOI: 10.1016/j.pneurobio.2005.02.004
Extraction: not-recorded · Review: verified · Source state: unknown
Machine extracted: no · Human scientist reviewed: no · Externally validated: no
Incomplete path: claim, extraction-status
Generated: 9/18/2026, 3:03:59 PM
Funding and conflicts are disclosed and considered, but sponsorship never automatically changes a tier. Corrections, retractions, and expressions of concern override the original rating.
This is a representative, sequence-derived model ordered by residue position only. It is not the peptide's experimentally determined or predicted biological conformation, and it carries no claim about real bond angles, distances, secondary structure, binding sites, or activity.
Evidence searched through: Not recorded
Last accountable review: Not recorded
These are documentary and scientific-review signals, not conclusions of harm, ineffectiveness, safety, or absence of research.
This maturity index describes evidence-base development and governance. It is not a probability of efficacy, safety, truth, medical advice, or regulatory approval. Read the methodology.